samedan logo
 
 
 
spacer
home > pmps > summer 2020 > practical tips to navigate the new normal
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Practical Tips to Navigate the New Normal

The life science sector is in a period of unprecedented transformation. Pharmaceutical manufacturing and packaging businesses have responded swiftly to requirements to pivot their business, producing and packaging new drugs and devices. This is in the context of unparalleled disruption to the supply chain.

The COVID-19 pandemic has accelerated processes throughout the industry. Changes that used to take months or years now take only a few weeks as life science companies support the global effort to find effective treatments for coronavirus SARS-CoV-2.

Every major manufacturer is experiencing disruption across supply chains, driven by volatility in the supply of parts and raw materials. Packaging and labelling sectors have had to respond to an unprecedented acceleration in the pace of change. In the pharma sector, many players have pivoted their operations to join in the race to develop a vaccine or repurpose existing drugs to treat COVID-19. The need to repurpose patient information labelling rapidly to meet regulatory requirements is an immediate challenge.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Gurdip Singh is CEO of Kallik, the market- leading enterprise labelling company, and a deeply experienced practitioner and leader in life science industry transformation. He previously held senior life science industry leadership roles at CSC, then DXC Technology, and is passionate about the user experience. Over Gurdipís career he has also worked extensively in the healthcare, life science and banking industry, giving him an insight into transferable/cross-industry best practice.
spacer
Gurdip Singh at Kallik
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement